ADRO Aduro Biotech, Inc.

11.00
-0.1  -0.9%
Previous Close 11.10
Open 11.05
Price To book 2.98
Market Cap 739.00M
Shares 67,182,000
Volume 182,716
Short Ratio 28.30
Av. Daily Volume 360,653

SEC filingsSee all SEC filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 17520730
  2. 8-K - Current report 17515970
  3. 8-K - Current report 162053969
  4. 8-K - Current report 162009092
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 161986820

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas - ECLIPSE trial
Pancreatic cancer
Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial
Pancreatic cancer
Phase 1/2 dosing initiated March 2016.Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
Epacadostat and CRS-207 - SEASCAPE
Ovarian cancer
Phase 2 trial to be initiated 1H 2017.
CRS-207
Mesothelioma - cancer

Latest News

  1. Aduro (ADRO) Inks License Agreement with Stanford University
  2. Aduro Biotech Enters into Exclusive License Agreement for Proprietary Neoantigen Identification Technology
  3. ETFs with exposure to Aduro BioTech, Inc. : January 17, 2017
  4. Aduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : January 16, 2017
  5. Aduro BioTech, Inc. – Value Analysis (NASDAQ:ADRO) : January 9, 2017
  6. ADURO BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  7. Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Gastric Cancer
  8. Aduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : January 6, 2017
  9. Announcement from PT Adaro Energy Tbk - Ir Soebianto
  10. Currency Conversion Rate for 2016 Interim Dividend Payment
  11. Australia lobbies China-led AIIB to add coal to lending priorities
  12. Coal in Trump’s Stocking
  13. Energy thinktank cuts coal demand forecast for fifth year in row
  14. Clean Energy ‘Moving Forward’ Despite Trump’s E.P.A. Pick, Experts Say
  15. Aduro Biotech to Present at the 35th Annual J.P. Morgan Healthcare Conference
  16. 2016 Dividend Interim Payment Schedule and Procedure
  17. ADURO BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
  18. Is Aduro BioTech Inc (ADRO) A Good Stock To Buy?
  19. Aduro Biotech Europe’s Hans van Eenennaam, Ph.D. and John Dulos, Ph.D. Honored with the Intellectual Property Owners Education Foundation’s 43rd Inventor of the Year Award for Contributions in the Discovery of KEYTRUDA® (pembrolizumab)
  20. Aduro Biotech Announces Anti-CD27 Agonist, an Investigational Anti-Cancer Immunotherapy, Advancing in Collaboration with MSD

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 17520730
  2. 8-K - Current report 17515970
  3. 8-K - Current report 162053969
  4. 8-K - Current report 162009092
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 161986820
  6. 8-K - Current report 161968046
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161967846
  8. 8-K - Current report 161948269
  9. 8-K - Current report 161885164
  10. 8-K - Current report 161804446